Evidence map›Paper›PMID 27687804›Full record

ArticleJournal of translational medicine2016

Gemcitabine reduces MDSCs, tregs and TGFβ-1 while restoring the teff/treg ratio in patients with pancreatic cancer.

Emma Eriksson, Jessica Wenthe, Sandra Irenaeus, Angelica Loskog, Gustav Ullenhag

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of translational medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 150 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
150citing papers in PubMed, 3 pooled it
6.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

150 citing papers in PubMed, 3 syntheses or guidelines pooled it, 212 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Single-Cell RNA Analysis Reveals Cell-Intrinsic Functions of CAR T Cells Correlating with Response in a Phase II Study of Lymphoma Patients.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023
    Trial
  7. Trial
  8. Trial
  9. Article
  10. Regulatory T cells in cancer and inflammation.Signal transduction and targeted therapy · 2026
    Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review

90 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Emma ErikssonDepartment of Immunology, Genetics and Pathology, Science for Life Laboratory, Rudbeck Laboratory C11 2nd floor, Uppsala University, Dag Hammarskjoldsvag 20, 751 85, Uppsala, Sweden.
Jessica WentheDepartment of Immunology, Genetics and Pathology, Science for Life Laboratory, Rudbeck Laboratory C11 2nd floor, Uppsala University, Dag Hammarskjoldsvag 20, 751 85, Uppsala, Sweden.
Sandra IrenaeusDepartment of Immunology, Genetics and Pathology, Science for Life Laboratory, Rudbeck Laboratory C11 2nd floor, Uppsala University, Dag Hammarskjoldsvag 20, 751 85, Uppsala, Sweden.
Angelica LoskogDepartment of Immunology, Genetics and Pathology, Science for Life Laboratory, Rudbeck Laboratory C11 2nd floor, Uppsala University, Dag Hammarskjoldsvag 20, 751 85, Uppsala, Sweden. angelica.loskog@igp.uu.se.
Gustav UllenhagDepartment of Immunology, Genetics and Pathology, Science for Life Laboratory, Rudbeck Laboratory C11 2nd floor, Uppsala University, Dag Hammarskjoldsvag 20, 751 85, Uppsala, Sweden.
Science for Life Laboratory · SEUppsala University Hospital · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCancer immunotherapy can be potentiated by conditioning regimens such as cyclophosphamide, which reduces the level of regulatory T cells (tregs). However, myeloid suppressive cells are still remaining. Accordingly to previous reports, gemcitabine improves immune status of cancer patients. In this study, the role of gemcitabine was further explored to map its immunological target cells and molecules in patients with pancreatic cancer.

methodsPatient blood was investigated by flow cytometry and cytokine arrays at different time points during gemcitabine treatment.

resultsThe patients had elevated myeloid-derived suppressor cells (MDSCs), and Tregs at diagnosis. Myeloid cells were in general decreased by gemcitabine. The granulocytic MDSCs were significantly reduced while monocytic MDSCs were not affected. In vitro, monocytes responding to IL-6 by STAT3 phosphorylation were prevented to respond in gemcitabine medium. However, gemcitabine could not prevent STAT3 phosphorylation in IL-6-treated tumor cell lines. TGFβ-1 was significantly reduced after only one treatment and continued to decrease. At the same time, the effector T cell:Treg ratio was increased and the effector T cells had full proliferative capacity during the gemcitabine cycle. However, after a resting period, the level of suppressor cells and TGFβ-1 had been restored showing the importance of continuous conditioning.

conclusionsGemcitabine regulates the immune system in patients with pancreatic cancer including MDSCs, Tregs and molecules such as TGFβ-1 but does not hamper the ability of effector lymphocytes to expand to stimuli. Hence, it may be of high interest to use gemcitabine as a conditioning strategy together with immunotherapy.

Indexed as

GemcitabineMDSCsPancreatic cancerTGFβTregs

Identifiers

PMID27687804
PMCPMC5041438
OpenAlexW2523973428

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.